ISG15: leading a double life as a secreted molecule.
- Author:
Dusan BOGUNOVIC
1
;
Stephanie BOISSON-DUPUIS
;
Jean Laurent CASANOVA
Author Information
1. St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA. dubo210@rockefeller.edu
- Publication Type:Review ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
- Keywords:
ISG15;
MSMD;
mycobacteria;
secreted molecule
- MeSH:
Amino Acid Sequence;
Animals;
Cytokines/chemistry/*secretion;
Humans;
Interferon-gamma/secretion;
Metabolism, Inborn Errors/metabolism;
Models, Biological;
Molecular Sequence Data
- From:Experimental & Molecular Medicine
2013;45(4):e18-
- CountryRepublic of Korea
- Language:English
-
Abstract:
ISG15 is a well-known intracellular ubiquitin-like molecule involved in ISGylation. However, a recent study has revived the notion first put forward two decades ago that ISG15 is also a secreted molecule. Human neutrophils, monocytes and lymphocytes can release ISG15, even though this protein has no detectable signal peptide sequence. ISG15 has also been found in the secretory granules of granulocytes. The mechanism underlying ISG15 secretion is unknown. Secreted ISG15 acts on at least T and natural killer (NK) lymphocytes, in which it induces interferon (IFN)-gamma production. However, the mechanism by which ISG15 stimulates these cells also remains unclear. ISG15 and IFN-gamma seem to define an innate circuit that operates preferentially, but not exclusively, between granulocytes and NK cells. Inherited ISG15 deficiency is associated with severe mycobacterial disease in both mice and humans. This infectious phenotype probably results from the lack of secreted ISG15, because patients and mice with other inborn errors of IFN-gamma immunity also display mycobacterial diseases. In addition to raising mechanistic issues, the studies described here pave the way for clinical studies of various aspects, ranging from the use of recombinant ISG15 in patients with infectious diseases to the use of ISG15-blocking agents in patients with inflammatory diseases.
